AUTHORS
Giuseppe Gaetano Loscocco, MD, PhD, Jasson Villarreal Hernandez, MD2, Javier Diaz-Carbonero, MD3, Chiara Paoli, PhD4, Paola Guglielmelli, MD, PhD5, Mario Tiribelli, MD6, Francesca Palandri, MD, PhD7, Jesus Maria Hernandez Rivas, MD8, Maria Laura Fox, MD9, Damian Cubillas, MD10, Graeme M Greenfield, MD11, Ciro Rinaldi, MD12, Priya Sriskandarajah, MD13, Fabrizio Pane Sr, MD14, Giuseppe Lanzarone, MD15, Daniela Cilloni, MD16, Matteo Pacilli, MD17, Massimo Breccia, MD18, Michael Lahn, MD19, Giusy Di Conza, PhD20, Tracey Hammett21, Paramjit Kaur, Phd22, Michael Emig, MD23, Karen Tonge24, Mireille Cantarini, MD25, Alessandro Lucchesi, MD, PhD26, Alessandro Vannucchi, MD27
AFFILIATIONS
1 AOU Careggi, University of Florence, Florence, Italy
2 Hematología Clínica, Institut Català d'Oncologia-Hospital Duran i Reynals, 08908-L'Hospitalet del Llobregat, Spain
3 Hematología Clínica, Institut Català d'Oncologia-Hospital Duran i Reynals, 08908-L'Hospitalet del Llobregat, Spain
4 AOU Careggi, University of Florence, Florence, Italy
5 AOU Careggi, University of Florence, Florence, Italy
6 University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
7 IRCSS Azienda Ospedaliera-Universitaria di Bologna, Bologna, Italy
8 Hospital Universitario de Salamanca: (University Hospital Salamanca), Salamanca, Spain
9 Vall d'Hebron University Hospital, Barcelona, Spain
10 HM Hospital Sanchinarro, Madrid, Spain
11 Johnston Cancer Research Centre, Queen’s University Belfast, Belfast Health and Social Care Trust, Belfast, United Kingdom
12 United Lincolnshire Teach Hospitals NHS Trust, Lincolnshire, United Kingdom
13 Guy´s and St. Thomas NHS Foundation Trust, London, United Kingdom
14 A.O.U. Federico II, Naples, Italy
15 Citta’ della Salute e della Scienza di Torino, Torino, Italy
16 AO Ordine Mauriziano di Torino, Turin, Italy
17 AOU Federico U.O.C. Grande Ematologia, Reggio Calabria, Italy
18 Sapienza University- Policlinico Umberto I, Rome, Italy
19 iOnctura, Geneva, Switzerland
20 iOnctura, Geneva, Switzerland
21 iOnctura, Geneva, Switzerland
22 iOnctura, Geneva, Switzerland
23 iOnctura, Geneva, Switzerland
24 iOnctura, Geneva, Switzerland
25 iOnctura, Geneva, Switzerland
26 IRCCS IRST Istituto Romagnolo per lo studio dei tumori “Dino Amadori”, Meldola, Italy
27 AOU Careggi, University of Florence, Florence, Italy
ABSTRACT
Introduction: Inhibition of both the Phosphoinositide 3-kinase (PI3K) pathway and Janus kinase (JAK) signaling leads to decreased proliferation of cells from patients (pts) with myelofibrosis (MF) in clonogenic assays. Roginolisib is a novel oral drug, which engages the adenosine triphosphate (ATP) pocket and induces a unique, PI3Kδ-specific conformational shift. This shift blocks the binding of ATP and locks the kinase in its inactive form. In MF, roginolisib is expected to have a dual mechanism of inhibition of pro-inflammatory signaling and effects on immune escape. During the first-in-human dose study, conducted in 44 patients (pts), including 36 pts with solid tumors and 8 with follicular lymphoma, the biologically effective dose was established as 80 mg once daily. Given its tolerability at the IC90 concentration, the present study assesses the safety and clinical activity of the combination of roginolisib and a JAK inhibitor (JAKi) in MF patients who are unresponsive to JAKis.
Methods: The HEMA-MED (IOA-244-203) is a prospective, multicenter, open-label Phase 1/2 study. The primary objective of this study is to evaluate the tolerability of roginolisib when administered in combination with an ongoing approved JAKi. Secondary objectives include: (a) changes in peripheral blood T regulatory cells; (b) splenic response rate (SRR) as assessed by MRI/CT; (c) proportion of patients with a reduction in Total Symptom Score (TSS) as measured by modified Myelofibrosis Symptom Assessment Form (mMFSAF). Key Inclusion criteria are (1) diagnosis of primary or secondary MF (2) prior treatment with an approved JAKi for ≥ 3 months, on a stable dose for ≥ 1 month prior to starting the add-on treatment, and unsatisfactory spleen reduction; (3) active symptoms of MF as assessed by Total Symptom Score (TSS) of ≥ 10; (4) platelet count ≥ 50 × 109/L and hemoglobin ≥8 g/dL. Prophylaxis for infection risk is not protocol mandated. The study is actively enrolling at sites in Italy, Spain and United Kingdom.
Results: As of 30 June 2026, 10 pts had received roginolisib at the 80 mg dose, in combination with either ruxolitinib (n=9) or fedratinib (n=1). Median age of pts was 66 years (range, 42–75), 7 were male, and ECOG performance status was 0 or 1 in 5 pts each. At a roginolisib median duration of treatment of 120 days (range 32-225), the combination was well tolerated allowing pts to remain on roginolisib and JAKi treatment. In 9/10 pts adverse events were grade 1 or 2, and 1/10 pts had a transient transaminase elevation Grade 3 that did not recur at subsequent doses. No roginolisib-related serious adverse events, no permanent dose reductions or discontinuations, and no requirement for intermittent dosing. Among the seven pts who had reached Week 12 (7/10), six (6/7; 86%) had a reduction in palpable spleen length, including five (5/7; 71%) with a reduction of ≥25%. Protocol-defined spleen volume assessments by MRI/CT are ongoing. All pts remain on study treatment and 2/10 have reached Week 24 and both have continued reductions in spleen length. Symptoms improved within the first 28 days: by Week 12, 71% (5/7) achieved TSS50, with improvements across multiple domains, including fatigue, pruritus, early satiety, and abdominal discomfort. Enrolment is ongoing, and correlative translational biomarker data will be analyzed. Updated data will be presented.
Conclusions: Roginolisib is a novel, conformation-selective, oral, allosteric modulator of PI3Kδ with a differentiated pharmacologic profile. Preliminary results from the HEMA-MED study show that roginolisib can be safely administered with continuous daily dosing in combination with continued JAKi. The early and consistent reductions in spleen size and symptom burden support the therapeutic potential of roginolisib as an add-on strategy in patients with MF and an inadequate response to JAK inhibitor. Longer follow-up, protocol-defined imaging, and translational analyses will further characterize the durability and biological basis of these encouraging clinical findings.
DISCLOSURES
Giuseppe Gaetano Loscocco, MD, PhD: AOP Health - Honoraria; AOP, GSK, Novartis - Honoraria; Novartis - Honoraria; GSK - Honoraria; GSK - Consultancy (Includes expert testimony)